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Introduction
Osteoporosis is often considered to be a type of bone
atrophy. The events which occur in bone at the time
of menopause include a generalized increase in its meta-
bolic activity. Agents including parathyroid hormone,
thyroid hormone, interleukin-1 (IL-1), IL-6, IL-11,
tumor necrosis factors, and epidermal growth factor,
increase osteoclast activation; on the other hand,
gonadal steroids are important inhibitors of activa-
tion, and their deficiency after menopause causes an
increase in activation frequency.1 Pastoureau et al2
and Thompson et al3 studied ovariectomized ewes and
baboons and indicated a 2- to 3-fold increase in the
metabolic activity of bone surfaces. The increased acti-
vity of bone due to estrogen deficiency is predomi-
nantly due to an increase in the incidence of bone
remodeling units. Estradiol inhibits IL-6 production
and estrogen deficiency may in this way stimulate osteo-
clast activation.4 Estrogen deficiency related to meno-
pause is clinically associated with a significant loss of
bone mineral density (BMD).5,6 In postmenopausal
women, hormone therapy (HT) has been shown to
effectively protect and augment existing bone mass
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and reduce the incidence of fracture of the vertebrae
and hip.6–9
Orally administered estrogen, the most frequently
used replacement therapy, can stimulate the synthesis 
of hepatic proteins and increase the circulating levels of
hormone-binding globulins and renin substrate.10,11
This effect has been attributed to the first-pass hepatic
metabolism of the large bolus of estrogen that is
absorbed by the intestine and delivered to the liver after
an oral dose. Transdermal administration of estrogen
avoids the first-pass hepatic effect and delivers estra-
diol to the general venous circulation at a continuous
rate.11,12 Our laboratory has demonstrated previously
that an increased serum estradiol (E2) slope 2 hours
after applying E2 gel 2.5 g/day in Asian women
allowed the elevation of the serum E2 concentration
to continue for 10 hours, with a peak estradiol level of
approximately 557 pg/mL at 6 hours and a return to
pretreatment level in 16 hours.13
It is generally accepted that a daily oral dose of
0.625 mg of conjugated equine estrogen or 1–2 mg
17β-estradiol is needed to prevent postmenopausal
bone loss.14–16 However, recent studies have indicated
that lower doses of estrogen may be effective for
maintaining bone mass.17–19 This study investigated
the efficacy of 3 doses of a 25-day transdermal 17β-
estradiol delivery system for the prevention of bone
loss in postmenopausal women.
Methods
Subjects
This prospective study covered 120 postmenopausal
women who were randomized and divided into 4
groups. There were no significant differences in baseline
demographic or clinical characteristics including age,
body mass index, smoking, physical activity and 
BMD among the 4 groups (Table 1). All participants
received calcium carbonate 500 mg/day of elemental
calcium. Group 1 comprised 30 women who received
E2 gel (Besins-lscovesco, Paris, France; 0.6 mg 17β-
estradiol/1g) 1.25g daily (containing 0.75mg estra-
diol) from day 1 to day 25 each month. It was applied
to the skin on both arms, preferably after washing in
the evening. Thirty women in group 2 were treated
with E2 gel at 2.5g (Besins-lscovesco; 1.5mg 17β-
estradiol), used as above. Thirty women in group 3
received E2 gel at 5.0g (Besins-lscovesco; 3 mg 17β-
estradiol). Medroxyprogesterone acetate (Provera®,
Upjohn, USA) 10 mg/day from cycle day 14 to 25
was given for every natural postmenopausal woman
who received the E2 gel treatment. Group 4 was com-
posed of 30 women who used estriol (Ovestin,
Organon, The Netherlands) 2 mg/day, and served as
controls. Estriol can be a safe and effective alternative
in the relief of climacteric symptoms in postmenopausal
women but it cannot prevent bone loss.20 Exclusion
criteria included known or suspected bone disease,
hypo- or hypercalcemia, vitamin D deficiency, and any
bone fracture within 6 months. Women were excluded
if they had ever undergone HT or taken bisphospho-
nates. All participants gave their written informed
consent before entry into the study. The surgical meno-
pausal women had suffered from uterine leiomyomata
or endometriosis and had received total hysterectomy
plus bilateral oophorectomy.
Quantitative computed tomography (QCT)
BMD was evaluated by 1 QCT at baseline (before
treatment), then at 6-month intervals thereafter for 
1 year. QCT was implemented on Somaton DRH
Table 1. Baseline characteristics of study population
Estriol (mg/d) Oestrogel®(g/d)
2 1.25 2.5 5
Subjects (n) 21 20 21 20
Age (yr) 49.1 51.3 48.9 54.2
Weight (kg) 54.2 54.9 58.2 55.1
Height (cm) 156.6 153.4 158.0 155.2
BMI (kg/m2) 22.1 23.3 23.3 22.9
Menopause type (n)
Natural 15 13 14 16
Surgical 6 7 7 4
Spine BMD (g/cm3) 113.2 ± 24.1 113.3 ± 21.3 111.2 ± 31.4 94.9 ± 31.1
BMI = body mass index; BMD = bone mineral density.
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Scanners (Siemens, Erlangen, Germany), with a single
dual-energy approach. The scanner was equipped with
an option for rapid kilovolt peak (KVP) switching 
and calibrated every day. The voltage was switched
between 125 and 85 KVP from pulse to pulse, which
allowed necessary data to be obtained at 2KVP values.
The BMD was measured by representative volume from
T12 to L3. The calcium and soft tissue equivalent-
density images were scaled in milligrams per milliliter.
Statistical analysis
The results of baseline demographic characteristics and
participant-related data between E2 gel and estriol
groups were presented as mean ± standard deviation
(SD) and analyzed using one-way analysis of variance
(ANOVA) test. The paired-sample t test was used to
examine BMD in each group before and after treat-
ment. The independent-sample t test was used to exam-
ine BMD difference between each group at same time.
The changes in BMD were analyzed as follows. For
treatment effects, ANOVA for repeated measures was
used to examine the changes in the E2 gel and estriol
groups independently. When patients were separated
into surgical and natural menopause groups, we used
Kruskal–Wallis test to examine the changes in BMD.
A post hoc test (Games–Howell) was used to examine
the level of significance of each E2 gel group compared
to the control group. Statistical analysis was performed
using SPSS version 11.5 (SPSS Inc., Chicago, IL,
USA). All analyses were 2-sided and performed at a 
p < 0.05 level of significance.
Results
A total of 120 women were enrolled and 82 (68%)
completed 1 year of treatment. Twenty-three women
did not complete the study because of discontinuing
the HT, 10 were lost to follow-up or relocated and 5
had mild adverse events. There were no significant dif-
ferences in baseline demographic or clinical characteris-
tics among the 4 groups (Table 1).
As shown in Table 2, all 3 treatment groups showed
increases from baseline in the mean BMD of the lumbar
spine, as detected by QCT at 6- and 12-month inter-
vals; however, the control group experienced a decrease
in bone mass. In the stratified subgroups of the natural
and surgical menopausal patients, the result in surgical
menopause groups was quite different; decreased BMD
was noted in the 2.5 mg group as compared to the
increased BMD in the other 2 groups. Significant bone
loss occurred at 12 months after estriol treatment
(p = 0.001).
Figure 1 shows the mean percentage of change,
from baseline, in the BMD of the lumbar spine after 6
and 12 months of treatment. All 3 estrogen treatment
groups showed significant increases in lumbar spine
BMD after 6 months of treatment (p < 0.05), except
the subjects in the E2 gel 1.25 g/day group at the 6-
month interval, in which a minimal increase was seen
(p = 0.232). There were significant changes between the
bone mass decrements in the treatment groups and the
control group at the 6-month period (p = 0.032) after
12 months of treatment (p = 0.004) (Table 2).
Table 2. Bone mass revolution after treatment with Oestrogel®and estriol
Subgroup Pretreatment
Post-treatment Change
p
6 mo 12 mo (%)*
Oestrogel®1.25 g/d (n = 20) 113.3 ± 21.3 113.7 ± 24.2 118.7 ± 22.0 4.82 0.017†
Surgical menopause (n = 7) 115.3 ± 14.6 114.7 ± 20.4 126.8 ± 10.0 9.99 0.278‡
Natural menopause (n = 13) 112.2 ± 24.7 113.3 ± 27.0 115.6 ± 24.7 3.09 0.032§
Oestrogel®2.5 g/d (n = 21) 111.2 ± 31.4 115.6 ± 31.4 114.2 ± 30.9 2.72 0.226†
Surgical menopause (n = 7) 115.6 ± 23.0 124.7 ± 23.5 125.1 ± 21.6 8.19 0.123‡
Natural menopause (n = 14) 109.0 ± 35.4 110.3 ± 35.0 108.8 ± 34.0 −0.19 0.925§
Oestrogel®5.0 g/d (n = 20) 94.9 ± 31.1 105.6 ± 31.0 103.0 ± 31.4 8.69 0.051†
Surgical menopause (n = 4) 80.5 ± 26.4 86.2 ± 8.8 94.1 ± 8.4 13.21 0.340‡
Natural menopause (n = 16) 98.5 ± 31.9 109.8 ± 32.6 106.1 ± 34.4 7.76 0.110§
Estriol 2 mg/d (n = 21) 113.2 ± 24.1 114.0 ± 27.2 108.6 ± 25.8 −1.44
Surgical menopause (n = 6) 106.3 ± 33.2 106.5 ± 41.6 98.5 ± 34.2 −7.40
Natural menopause (n = 15) 116.0 ± 20.2 116.7 ± 22.0 112.6 ± 21.7 −2.91
*Change (%) = BMD after 12-month treatment − baseline BMD/baseline BMD × 100%; †12-month post-treatment of Oestrogel® versus estriol 2 mg/day; ‡12-month
post-treatment of Oestrogel® versus estriol in surgical menopausal women; §12-month post-treatment of Oestrogel® versus estriol in natural menopausal
women.
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Figure 2 shows that the increments of lumbar spine
BMD in the E2 gel 2.5 g/day groups were more pro-
minent in surgical menopausal women (p = 0.019) than
in the natural menopause groups (p = 0.080) com-
pared with the decrements in the control group after
12 months of treatment. The difference may be due to
case variation. No statistical significance was found in the
E2 gel 1.25g/day groups, with p = 0.167 and p=0.157
for oophorectomized and intact ovary women, respec-
tively. Significant difference was observed in both
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Figure 1. Mean percentage change from baseline for bone mineral density of the lumbar spine with active treatment of Oestrogel®
and estriol.
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Figure 2. Mean percentage change from baseline for bone mineral density of the lumbar spine with 12-month treatment of Oestrogel®
and estriol in surgical and natural menopause women.
J Chin Med Assoc • May 2007 • Vol 70 • No 5204
T.S. Yang, et al
groups (p = 0.013 and p = 0.028, respectively) in the
E2 gel 5 g/day groups, which obtained substantial
increases in BMD, compared with the decrements in
the control groups.
Discussion
In the present study, we confirmed the efficacy of the
lower-dose transdermal delivery of 17β-estradiol for
preventing postmenopausal bone loss.17–20 In contrast
to the control group (estriol, 2 mg/day), there were
increases in lumbar spine BMD, detected by QCT at 
6 months in the 2.5 and 5.0g/day groups, which were
maintained to 12 months. In the 1.25 g/day group,
there was a minimal increase in lumbar spine BMD at
6 months, in accordance with the report of Riggs’
group that little difference had been achieved initially
in the half-dose (estradiol, 0.025 mg/day) group, then
a significant difference in lumbar spine BMD from a
placebo occurred later.18
The most widely prescribed doses of estrogen
(0.625 mg/day of conjugated estrogen or 1 mg/day
of 17β-estradiol orally, and 50 μg/day transdermally)
have been believed to be at or near the minimal effec-
tive dose for preventing postmenopausal bone loss.19
However, an effective low dose of estrogen has always
been a goal for investigators to pursue. Horsman et al15
treated 120 postmenopausal women with ethinyl estra-
diol and found no beneficial effects on BMD with daily
doses of 25 or 15 μg. Lindsay et al16 observed that
daily dose levels of less than 0.625 mg of conjugated
equine estrogen were essentially ineffective in prevent-
ing bone loss. The most recent report showing no ben-
efit from low-dose estrogen was a case-control study in
which Michaelsson et al14 demonstrated that low doses
of estrogen (conjugated estrogen <0.625 mg/day,
estradiol <2mg/day, ethinyl estradiol <10μg/day, or
transdermal estradiol <50μg/day) had less effectiveness
in preventing hip fractures in senile women (mean
age, 72.5 ± 6.8 years). These results might be due to
the lower accuracy of older instrumentation, or be limi-
ted by confounding bias and low statistical power in the
subgroup analyses.19 Most recent studies have shown
the efficacy of low doses of estrogen. Genant et al17
demonstrated that 0.3 mg of conjugated estrogen 
was able to preserve BMD. Estradiol (0.5 mg) adminis-
tered orally, as prescribed by Dr Ettinger, showed 
a preservation of BMD in the lumbar spine at 18
months.21 A 2-year prospective study of the Trans-
dermal Estradiol Investigation Group has demonstra-
ted that doses of transdermal E2 as low as 25 μg/day
prevented osteoporosis in postmenopausal women.19
Our current study reaffirmed the effective low dose
concept for the prevention of postmenopausal bone
loss; although the one-half dose maintained BMD at
6 months of active treatment, it did improve BMD
significantly at 12 months.
Oophorectomy has a profound impact on women,
especially premenopausal subjects.22–24 Since the ovary
is the major site for the production of estradiol (90%),
testosterone (50%) and androstenedione (50%), natu-
rally occurring menopause is associated with a marked
decline in serum concentrations of estradiol and andro-
stenedione, but not testosterone, because the post-
menopausal ovary produces even more testosterone.
The fact that postmenopausal ovaries continue to
secrete testosterone was revealed by Judd et al.25 Ohta
et al24 found that serum levels of estrone and andro-
stenedione were significantly lower in oophorecto-
mized women than in natural menopausal women.
Laughlin et al26 demonstrated that among oophorec-
tomized women, total and bioavailable testosterone
levels were 40–50% lower than those in intact women
throughout the 50–89 year age range, while andro-
stenedione levels decreased 27% and sex-hormone bind-
ing globulin levels increased 30%. Thus, the presence 
or absence of ovaries which produce testosterone or
other unknown substances may play a crucial role in
the subsequent decades of life in natural or surgical
menopausal women.
Both estrogens and androgens play an important
role in increasing and maintaining BMD.27 The assum-
ption that estrogens may play a more critical role than
androgens in bone maturation and mineralization is
partly derived from the studies of mutations in patients
with defective estrogen receptors or mutated aromatase
cytochrome P450 (CYP 19).28,29 In hypogonadal men
and prostate cancer patients who had received andro-
gen deprivation therapy, a marked decrease in bone
density was observed; the BMD was modestly increased
by testosterone replacement therapy.30–32 Cell culture
studies using human osteoblast-like cells have shown
specific androgen receptors, through which the effects
of testosterone on bone may be mediated.33 Androgen
may promote the proliferation and differentiation of
osteoblasts, inhibit osteoclast recruitment or affect
osteoblast-to-osteoclast signaling.34 The aromatiza-
tion of testosterone to estradiol is another important
way that androgens exert their action on the male
skeleton.28,29,34,35 The same may be true for the female
skeleton where androgens act. Recently, Arisaka et al36
demonstrated that girls with congenital adrenal hyper-
plasia had significantly higher BMD than girls with
central precocious puberty. Their finding suggested
that adrenal androgen, as well as estrogen, played an
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important role in increasing BMD, and adrenal andro-
gen might act on bone not only as androgen, but as
estrogen after having been metabolized into an aroma-
tized bone-active compound in the peripheral tissues,
such as bone and fat. Therefore, androgens may have a
more important role in increasing BMD than previ-
ously realized. The postmenopausal ovaries, where
more androgens can be produced, may have some
advantages that oophorectomized women do not
have, thus, a difference in BMD ensues. In this study,
we demonstrated a more rapid loss of bone minerals in
oophorectomized women than in natural menopause
women in the control group and a prominent response 
to estrogen replacement therapy in women without
ovaries treated with E2 gel (Figure 2).
Several techniques are available for the clinical
measurement of BMD. In QCT, a thin transverse slice
through the body is imaged, and then the image can
be quantitated to give a measure of volumetric BMD.
Cancellous bone can be measured independently of
the surrounding cortical bone, osteoarthritis and aortic
calcification. Only dual-energy X-ray absorptiometry
(DXA) or bone densitometry and QCT are able to
measure BMD in the spine, where a 0:100 cortical to
cancellous bone ratio can be taken by QCT, a 50:50
ratio by an anterior–posterior DXA view and a 10:90
ratio by a lateral DXA view, hence, the site of choice
to measure responsiveness to therapy.37 However, the
radiation dose of QCT is significantly higher than
when using absorptiometric techniques, which limits
the number of repeated measurements that are possible.
Capital and running costs of QCT are so high that an
installation solely for bone mineral measurement is not
generally feasible. With DXA, a measurement of the
density of the proximal femur is the most useful for pre-
dicting fractures and measurement of lumbar spine
density is the most useful for monitoring therapy.6
However, QCT is more accurate than DXA. Quanti-
tative ultrasonography (QUS) has not yet been exten-
sively validated; the sensitivities and specificities of the
QUS parameters are not high enough for QUS to be
used as an alternative to DXA.38
The limitations of this study include the following:
lack of blinding; lack of true placebo control group;
small numbers; short follow-up; lack of power to dis-
tinguish difference among doses; no measures of
drug compliance. However, according to the results
of this preliminary study, it is worthy to perform a
larger, serious, randomized, double-blind, placebo-
controlled trial.
The positive effects of HT on the signs and symp-
toms of postmenopausal estrogen deficiency and the
long-term effects of reducing morbidity and mortality
from cardiovascular disease and osteoporotic fracture
are well known.6,9,39,40 However, most postmenopausal
women do not initiate HT and of those who do, most
discontinue therapy within 2 years, depriving them-
selves of the potential long-term benefits.41 Among
the reasons cited for not starting or for discontinuing
HT are the risk of cancer, presence of side-effects and
presence of uterine bleeding.42,43 The challenge is to
overcome the hesitations of women to continue long-
term therapy with HT. A low-dose transdermal delivery
system that prevents bone loss is an important option
that may address the problem of long-term comp-
liance by reducing dose-related adverse events or offer-
ing alternative delivery systems for postmenopausal
women to choose with ease.
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